Latest On Fate Therapeutics, Inc (FATE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 02:16 EST | News | Fate Therapeutics: The Future Remains Cloudy | N/A |  |
| 2023-05-03 23:29 EST | News | Fate Therapeutics GAAP EPS of -$0.19 beats by $0.47, revenue of $58.98M beats by $25.45M | N/A | |
| 2023-05-03 23:28 EST | News | Fate Therapeutics, Inc. (FATE) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-02 22:13 EST | News | Fate Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-03-24 09:55 EST | News | Fate Therapeutics: If You Are Comparing With Geron, Do It Thoroughly | N/A | |
About Fate Therapeutics, Inc (FATE):
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the develo read more...pment and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
General
- Name Fate Therapeutics, Inc
- Symbol FATE
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 279
- Fiscal Year EndDecember
- IPO Date2013-10-01
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.fatetherapeutics.com
Valuation
- Price/Sales (Trailing 12 Mt.) 231.92
- Price/Book (Most Recent Quarter) 21.59
- Enterprise Value Revenue 251.74
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.86
- Next Year EPS Estimate -$2.17
- Next Quarter EPS Estimate -$0.41
- Operating Margin -407%
- Return on Assets -17%
- Return on Equity -55%
- Revenue 31.43 million
- Earnings Per Share -$1.22
- Revenue Per Share $0.38
- Gross Profit -94189000
- Quarterly Earnings Growth 467.3%
Highlights
- Market Capitalization 8.06 billion
- EBITDA -76343000
- PE Ratio -2.38
- Analyst Target Price $113.65
- Book Value Per Share $4.38
Share Statistics
- Shares Outstanding 93.78 million
- Shares Float 79.71 million
- % Held by Insiders 179%
- % Held by Institutions 100.89%
- Shares Short 10.3 million
- Shares Short Prior Month 9.63 million
- Short Ratio 11
- Short % of Float 15%
- Short % of Shares Outstanding 11%
Technicals
- Beta 1.65
- 52 Week High $121.16
- 52 Week Low $19.81
- 50 Day Moving Average 95.77
- 200 Day Moving Average 71.47
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Fate Therapeutics, Inc (FATE) Dividend Calendar:
Fate Therapeutics, Inc (FATE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Fate Therapeutics, Inc (FATE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Fate Therapeutics, Inc (FATE) Chart:
Fate Therapeutics, Inc (FATE) News:
Below you will find a list of latest news for Fate Therapeutics, Inc (FATE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Fate Therapeutics, Inc (FATE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest FATE Trades:
Fate Therapeutics, Inc (FATE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-19 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-19 | 8-K (Current report) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-08-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-06 | D (Notice of Exempt Offering of Securities) | |
| 2020-06-18 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-06-18 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-06-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-10 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-06-10 | 8-K (Current report) | |
| 2020-06-08 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-05-11 | 8-K (Current report) | |
Fate Therapeutics, Inc (FATE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Fate Therapeutics, Inc (FATE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 179%
Institutional Ownership: 10089%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-05 | CINDY TAHL | General Counsel and Secretary | Sell | 16,682.00 | 50.55 | 843,253.41 | 102,118.00 | |
| 2020-11-05 | CINDY TAHL | General Counsel and Secretary | Buy | 9,282.00 | 2.73 | 25,339.86 | 108,800.00 | |
| 2020-11-05 | CINDY TAHL | General Counsel and Secretary | Buy | 10,000.00 | 2.90 | 29,000.00 | 118,800.00 | |
| 2020-11-05 | CINDY TAHL | General Counsel and Secretary | Sell | 2,600.00 | 51.15 | 132,998.58 | 99,518.00 | |
| 2020-11-04 | CINDY TAHL | General Counsel and Secretary | Buy | 51,519.00 | 2.73 | 140,646.87 | 151,037.00 | |
| 2020-11-04 | CINDY TAHL | General Counsel and Secretary | Sell | 51,519.00 | 50.41 | 2,597,139.76 | 99,518.00 | |
| 2020-10-16 | CINDY TAHL | General Counsel and Secretary | Buy | 29,199.00 | 2.73 | 79,713.27 | 128,717.00 | |
| 2020-10-16 | CINDY TAHL | General Counsel and Secretary | Sell | 29,199.00 | 50.25 | 1,467,211.79 | 99,518.00 | |
| 2020-10-01 | CINDY TAHL | General Counsel and Secretary | Sell | 6,260.00 | 41.09 | 257,234.04 | 106,501.00 | |
| 2020-10-01 | CINDY TAHL | General Counsel and Secretary | Sell | 21,757.00 | 40.26 | 875,902.01 | 112,761.00 | |
| 2020-10-01 | CINDY TAHL | General Counsel and Secretary | Buy | 35,000.00 | 2.73 | 95,550.00 | 134,518.00 | |
| 2020-10-01 | CINDY TAHL | General Counsel and Secretary | Sell | 6,983.00 | 41.95 | 292,929.17 | 99,518.00 | |
| 2020-09-14 | Bahram Valamehr | Chief Development Officer | Sell | 600.00 | 34.65 | 20,791.98 | 111,611.00 | |
| 2020-09-14 | Bahram Valamehr | Chief Development Officer | Buy | 21,924.00 | 2.90 | 63,579.60 | 112,211.00 | |
| 2020-09-14 | Daniel D Shoemaker | Chief Scientific Officer | Sell | 5,713.00 | 37.12 | 212,073.99 | 118,091.00 | |
| 2020-09-14 | Daniel D Shoemaker | Chief Scientific Officer | Sell | 17,887.00 | 36.11 | 645,908.51 | 123,804.00 | |
| 2020-09-14 | Daniel D Shoemaker | Chief Scientific Officer | Sell | 1,400.00 | 35.40 | 49,557.06 | 141,691.00 | |
| 2020-09-14 | Bahram Valamehr | Chief Development Officer | Sell | 600.00 | 37.49 | 22,494.00 | 87,211.00 | |
| 2020-09-14 | Bahram Valamehr | Chief Development Officer | Sell | 7,016.00 | 36.93 | 259,084.74 | 87,811.00 | |
| 2020-09-14 | Bahram Valamehr | Chief Development Officer | Buy | 3,076.00 | 1.69 | 5,198.44 | 90,287.00 | |